|
Bieżący numer
Archiwum
Artykuły zaakceptowane
O czasopiśmie
Rada naukowa
Bazy indeksacyjne
Kontakt
Zasady publikacji prac
Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
 
|
2/2025
vol. 100 Artykuł oryginalny
The clinical course of varicella and herpes zoster in children with inflammatory bowel disease – a prospective study
Magdalena Chazan
1
,
Ewa Talarek
2
,
Kinga Kowalska-Duplaga
3
,
Katarzyna Kamila Bąk-Drabik
4
,
Mariusz Szczepanik
5
,
Sabina Więcek
6
,
Marcin Banasiuk
1
,
Andrzej Radzikowski
1
,
Aleksandra Banaszkiewicz
1
Pediatr Pol 2025; 100 (2): 141-150
Data publikacji online: 2025/06/06
Plik artykułu:
- The clinical course (1).pdf
[0.20 MB]
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Kennedy PGE, Gershon AA. Clinical features of varicella-zoster virus infection. Viruses 2018; 10: 609. 2.
Wisniewski A, Kirchgesner J, Seksik P, et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterol J 2019; 8: 303-313. 3.
Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis 2021; 15: 879-913. 4.
Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2392-2403. 5.
Keene JK, Lowe DK, Grosfeld JL. Dissemunated varicella complicating ulcerative colitis. JAMA 1978; 239: 45-46. 6.
Deutsch DE, Olson AD, Kraker S, et al. Overwhelming pneumonia in a patient with Crohn’s disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr 1995; 20: 351-353. 7.
Mouzas IA, Greenstein AJ, Giannadaki E, et al. Management of varicella infection during the course of inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1534-1537. 8.
Vergara M, Brullet E, Campo R, et al. Fulminant infection caused by varicella herpes zoster in patients with Crohn disease undergoing treatment with azathioprine. Gastroenterol Hepatol 2001; 24: 47. 9.
Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-729. 10.
Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31. 11.
Triantafillidis JK, Cheracakis P. Severe infection by varicella virus in an adult with ulcerative colitis: favourable response to acyclovir treatment. Dig Liver Dis 2002; 34: 383-384. 12.
Bernal I, Domenech E, Garcia-Planella E, et al. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. J Gastroenterol Hepatol 2003; 26: 19-22. 13.
Lemyze M, Tavernier JY, Chevalon B, et al. Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn’s disease. Rev Mal Respir 2003; 20: 773-776. 14.
Leung VS, Nguyen MT, Bush TM Disseminated primary varicella after initiation of infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 2503-2504. 15.
Tougeron D, Mauillon J, Tranvouez JL. Severe varicella infection during treatment with infliximab for Crohn’s disease. J Gastroenterol Clin Biol 2006; 30: 1410-1413. 16.
Springfeld C, Sauerbrei A, Filusch A, et al. Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virus. J Clin Virol 2009; 44: 70-73. 17.
Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy an Australian and new Zealand experience. J Gastroenterol Hepatol 2010; 25: 1732-1738. 18.
Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70: 616-623. 19.
Kunz AN, Rajnik M. Disseminated cutaneous varicella zoster virus infections during infliximab therapy for Crohn’s disease case report of two pediatric patients at one institution. Clin Pediatr (Phila) 2011; 50: 559-561. 20.
Slynko O, Chojnicki M, Marszałek A, et al. [Favourable course of complicated varicella in immunocompromised patient – case report]. Now Lek 2013; 82: 186-189. 21.
Meriglier E, Coudroy R, Agius G. [Fatal fulminant varicella-zoster virus hepatitis in a female patient with Crohn’s disease treated by an anti-TNF alpha agent]. Med Mal Infect 2014; 44: 484-486. 22.
Nishimura S, Yoshino T, Fujikawa Y, et al. A rare case of ulcerative colitis exacerbated by VZV infection. Clin J Gastroenterol 2015; 8: 390-392. 23.
Abreu C, Santos L, Magro F. Varicella complicating by severe pneumonia and shock in an immunosuppressed Crohn’s disease patient under azathioprine and anti-tumor necrosis factor alpha. J Crohn Colitis 2015; 9: 1176-1178. 24.
Korelitz BI, Fuller SR, Warman JL, et al. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999; 94: 424-426. 25.
Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurineand azathioprinetherapy in pediatric patients with severe ulcerative colitis J Pediatr Gastroenterol Nutr 1999; 28: 54-58. 26.
Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000; 95: 3490-3497. 27.
Russell RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr 2001; 32: 207-208. 28.
Baumgart DC, Dignass AU. Shingles following infliximab infusion. Ann Rheum Dis 2002; 61: 661. 29.
Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn’s disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-111. 30.
Friesen CA, Calabro C, Christensen K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: 265-269. 31.
Shin BS, Seo HD, Na CH, et al. Case of herpes zoster duplex bilateralis. J Dermatol 2009; 36: 95-97. 32.
Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010; 4: 444-449. 33.
Monaghan TM, Norton B. Varicella pneumonia in an immunocompromised inflammatory bowel disease patient. Inflamm Bowel Dis 2010; 16; 364-365. 34.
Cullen G, Krakower D, Mitty JA, et al. Varicella zoster meningoradiculitis in Crohn’s disease treated with 6-mercaptopurine. Inflamm Bowel Dis 2011; 17: E109-110. 35.
Cruz MJ, Badrier T, Ferreira O, et al. Herpes zoster at the site of infliximab infusion: case report. Cutan Ocul Toxicol 2011; 30: 236-238. 36.
Ma Ch, Walters B, Fedorak RN. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn’s disease. World J Gastroenterol 2013; 19: 3347-3351. 37.
Wang X, Zhao J, Zhu S, Xia B. Herpes zoster in Crohn’s disease during treatment with infliximab. Eur J Gastroenterol Hepatol 2014; 26: 237-239. 38.
Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 2018; 24: 2258-2265. 39.
Garbo GM, Macaluso FS, Renna S, et al. Herpes zoster eruption during vedolizumab therapy: a simple coincidence or more? Inflamm Bowel Dis 2020; 26: e51-e52. 40.
Santos DH, Carneiro de Oliveira RM, Junior WRF, et al. Myelorradiculitis due to varicella zoster (Elsberg syndrome) as the first symptom of HIV in a patient with Crohn’s disease in use of Infliximab. Mult Scler Relat Disord 2021; 47: 102643. 41.
D’Arienzo D, Gryte KR, Noya F, et al. Disseminated and central nervous system vaccine-strain herpes zoster infection in a teenager with Crohn’s Disease on maintenance adalimumab therapy. JPGN Rep 2021; 2: e072 42.
Celada-Sendino M, Carballo-Folgoso L, de Francisco R, et al. Varicella zoster virus encephalitis: a potentially serious complication during treatment with vedolizumab. Rev Esp Enferm Dig 2023; 115: 271-272. 43.
Lyman KA, Sreekrishnan A, Thatikunta P, et al. Varicella zoster vasculopathy exacerbated by tofacitinib in a patient with ulcerative colitis. Stroke 2023; 54: e246-e250. 44.
Uchiyama E, Yamaguchi R, Anzawa K, et al. Vasculitis-like herpes zoster in the course of treatment with tofacitinib in ulcerative colitis: an assessment of local viral distribution by RNA in situ hybridization. J Dermatol 2024; 54: e246-e250. 45.
Leuvenink R, Aeschlimann F, Baer W, et al. Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression. Pediatr Rheumatol Online J 2016; 14: 34. 46.
Nicolai R, Cortis E, Ravà L, et al. Herpes virus infections during treatment with etanercept in juvenile idiopathic arthritis. J Pediatric Infect Dis Soc 2016; 5: 76-79. 47.
Khan N, Trivedi C, Shah Y, et al. The severity of herpes zoster in inflammatory bowel disease patients treated with anti-TNF agents. Inflamm Bowel Dis 2018; 24: 1274-1279. 48.
Santella C, Bitton A, Filliter C, et al. Anti-TNF therapy and the risk of herpes zoster among patients with inflammatory bowel disease. Inflamm Bowel Dis 2022; 28: 176-182. 49.
Nugent Z, Singh H, Targownik LE, et al. Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: is there still an unmet need? Inflamm Bowel Dis 2019; 25: 532-540. 50.
Szenborn L, Kraszewska-Głomba B, Jackowska T, et al. Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections. J Infect Chemother 2016; 22: 65-71. 51.
Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-468. 52.
Widgren K, Persson Berg L, Mörner A, et al. Severe chickenpox disease and seroprevalence in Sweden – implications for general vaccination. Int J Infect Dis 2021; 111: 92-98. 53.
Helmuth IG, Poulsen A, Suppli CH, et al. Varicella in Europe – a review of the epidemiology and experience with vaccination. Vaccine 2015; 33: 2406-2413. 54.
Bieńkowski C, Talarek E, Pokorska-Śpiewak M. The clinical course of herpes zoster is similar in immunocompetent and immunocompromised paediatric patients. J Paediatr Child Health 2023; 59: 1112-1114. 55.
Kanamori K, Shoji K, Kinoshita N, et al. Complications of herpes zoster in children. Pediatr Int 2019; 61: 1216-1220. 56.
Grote V, von Kries R, Rosenfeld E, et al. Immunocompetent children account for the majority of complications in childhood herpes zoster. J Infect Dis 2007; 196: 1455-1458. 57.
Hwang JH, Kim KH, Han SB, et al. A clinico-epidemiological multicenter study of herpes zoster in immunocompetent and immunocompromised hospitalized children. Clin Exp Vaccine Res 2019; 8: 116-123. 58.
Tsai TY, Wu JF, Weng MT, et al. Exacerbated gastrointestinal symptoms and long COVID in IBD patients with SARS-CoV-2 infection: a multi-center study from Taiwan. J Formos Med Assoc 2024; 123: 866-874. 59.
Axelrad JE, Cadwell KH, Colombel JF, et al. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. Therap Adv Gastroenterol 2021; 14: 1-17.
Copyright: © 2025 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
|
ENGLISH
